Long-term prophylaxis in hereditary angio-oedema: A systematic review

BMJ Open

Volumn 2, Issue 4, 2012, Pages

  Costantino, Giorgio ^a   Casazza, Giovanni ^a   Bossi, Ilaria ^a   Duca, Piergiorgio ^a   Cicardi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; DANAZOL; HEPARIN; METHYLTESTOSTERONE; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; PROPHYLAXIS; TREATMENT DURATION;

EID: 84864086115     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000524     Document Type: Article

References (28)

1. Blanch A, Roche O, Urrutia I, et al. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006;118:1330-5. (Pubitemid 44854110)
2. Lopez-Lera A, Favier B, Mena de la Cruz B, et al. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol 2010;126:1307-10.
3. Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005;94:498-503. (Pubitemid 40547939)
4. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24.
5. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009;161:1153-8.
6. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998;199:358-65. (Pubitemid 28404355)
7. Prada AE, Zahedi K, Davis AE 3rd. Regulation of C1 inhibitor synthesis. Immunobiology 1998;199:377-88. (Pubitemid 28404357)
8. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74. (Pubitemid 43255068)
9. Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006;101:619-27. (Pubitemid 43340941)
10. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206-15.
11. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139:379.
12. Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66:192-6.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
14. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
15. Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Books, 2003.
16. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:26.
17. Weiler JM, Quinn SA, Woodworth GG, et al. Does heparin prophylaxis prevent exacerbations of hereditary angioedema? J Allergy Clin Immunol 2002;109:995-1000. (Pubitemid 34634311)
18. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. NEJM 1996;334:1630-4. (Pubitemid 26192522)
19. Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. NEJM 1972;286:808-12.
20. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. NEJM 1972;287:452-4.
21. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. NEJM 1976;295:1444-8. (Pubitemid 8003704)
22. Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med 1977;86:306-8. (Pubitemid 8055510)
23. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. NEJM 2010;363:513-22.
24. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007;120:654-8. (Pubitemid 47320768)
25. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61. (Pubitemid 351238551)
26. Cicardi M, Bork K, Caballero T, et al HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147-57.
27. Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009;49:1987-95.
28. Agostoni A, Cicardi M, Martignoni GC, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980;65:75-9. (Pubitemid 10211125)